908 Devices Inc Ordinary Shares MASS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MASS is a good fit for your portfolio.
News
-
908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook
-
908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering
-
908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024
-
908 Devices Trace Chemical Identification Technology Adopted by European Agencies
-
908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook
-
908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares’ Fully Integrated Cell Therapy Manufacturing Platform
-
908 Devices to Participate in Upcoming Investor Conferences
-
908 Devices to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
Trading Information
- Previous Close Price
- $5.67
- Day Range
- $5.60–6.07
- 52-Week Range
- $4.85–12.51
- Bid/Ask
- $5.65 / $5.66
- Market Cap
- $194.81 Mil
- Volume/Avg
- 254,034 / 173,514
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.61
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
908 Devices Inc manufactures medical devices. It has developed a suite of purpose-built handheld and desktop mass spectrometry, or Mass Spec, devices for the point-of-need. Mass Spec devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the critical problems in life sciences research, bioprocessing, industrial biotech, forensics, and adjacent markets. The company geographically derives maximum revenue from United States, and also has its presence in Europe, Middle East and Africa, Americas and Other and Asia Pacific.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 230
- Website
- https://www.908devices.com
Comparables
Valuation
|
Metric
|
MASS
|
EMBC
|
300760
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 3.22 | 32.25 |
Price/Book Value | 1.19 | — | 10.21 |
Price/Sales | 3.61 | 0.52 | 10.27 |
Price/Cash Flow | — | 5.02 | 29.32 |
Price/Earnings
MASS
EMBC
300760
Financial Strength
|
Metric
|
MASS
|
EMBC
|
300760
|
|---|---|---|---|
Quick Ratio | 6.86 | 1.55 | 2.27 |
Current Ratio | 7.71 | 2.20 | 2.69 |
Interest Coverage | −213.38 | 1.59 | 6,354.72 |
Quick Ratio
MASS
EMBC
300760
Profitability
|
Metric
|
MASS
|
EMBC
|
300760
|
|---|---|---|---|
Return on Assets (Normalized) | −12.31% | 12.52% | 24.38% |
Return on Equity (Normalized) | −15.14% | — | 34.27% |
Return on Invested Capital (Normalized) | −17.75% | 30.00% | 31.97% |
Return on Assets
MASS
EMBC
300760
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Xyxyktgkd | Xfchdz | $184.2 Bil | |
SYK
| Stryker Corp | Nqjgwhzwh | Qkz | $125.1 Bil | |
MDT
| Medtronic PLC | Pljpnrzv | Vzpbxkb | $108.5 Bil | |
BSX
| Boston Scientific Corp | Nqmqzvyt | Yhnfgk | $107.1 Bil | |
EW
| Edwards Lifesciences Corp | Xxckdcbmv | Jytjx | $51.4 Bil | |
DXCM
| DexCom Inc | Wnjyhfpgk | Bvbqb | $50.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Tybzlbwvg | Fjnj | $25.0 Bil | |
PHG
| Koninklijke Philips NV ADR | Gfvpctdp | Bpjnkt | $24.4 Bil | |
ALGN
| Align Technology Inc | Qgcqnkgfr | Hrgzfdd | $21.7 Bil | |
PODD
| Insulet Corp | Xymxjmwdf | Yvsnwg | $12.2 Bil |